Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03007472 · ClinicalTrials.gov registry record · NA

Clinical Evaluation of the Cochlear Nucleus CI532 Cochlear Implant in Adults

A NA study of Hearing Loss, Sensorineural, sponsored by Cochlear.

Completed
Registry status
NA
Development phase
96
Enrollment target
10
Study locations

NCT03007472 is a NA study of Hearing Loss, Sensorineural that has completed, run by Cochlear. The registered enrollment target is 96 participants, below the 781-participant average among 20 other Hearing Loss, Sensorineural trials with a reported enrollment target (88% lower). The trial reports 10 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03007472, a NA study of Hearing Loss, Sensorineural, has completed, sponsored by Cochlear.

COMPLETED
Registry status
NA
Development phase
96 participants
Enrollment target
10
Study locations

Study Summary

The purpose of this study is to gather long-term data on the FDA approved CI532 cochlear implant, and CP1000 (Nucleus 7) sound processor

Interventions

  • DEVICE CI532
  • DEVICE Nucleus 7

Study Locations (10)

Missouri

  • The Center for Hearing and Balance Disorders - Chesterfield
  • Midwest Ear Institute - Kansas City
  • Washington University - St Louis

Colorado

  • Rocky Mountain Ear Center - Englewood

Iowa

  • University of Iowa - Iowa City

Michigan

  • University of Michigan - Ann Arbor

New York

  • New York University - New York

Ohio

  • The Ohio State University - Columbus

Oklahoma

  • Hearts for Hearing - Oklahoma City

Texas

  • Dallas Ear Institute - Dallas

Trial Details

FieldValue
Enrollment Target 96 participants
Start Date 2017-02-15
Est. Completion 2020-03-06
Phase NA

Sponsor

Cochlear

34 total trials

What the Registry Record Tells You About NCT03007472

The ClinicalTrials.gov registry entry for NCT03007472 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 781-participant average among 20 other Hearing Loss, Sensorineural trials with a reported enrollment target (88% lower). The listed sponsor is Cochlear, which has 34 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hearing Loss, Sensorineural appearing as the primary indexed condition, and to 2 interventions - of which CI532 is the first listed.

NCT03007472 reports 10 study locations spanning 8 distinct geographic areas - top geographies include Missouri, Colorado, Iowa.

Frequently Asked Questions

What is clinical trial NCT03007472 about?

NCT03007472 is a clinical study titled "Clinical Evaluation of the Cochlear Nucleus CI532 Cochlear Implant in Adults". The purpose of this study is to gather long-term data on the FDA approved CI532 cochlear implant, and CP1000 (Nucleus 7) sound processor

What is the current status of trial NCT03007472?

This trial is currently completed. It is a NA study. The enrollment target is 96 participants. The study started on 2017-02-15. Estimated completion is 2020-03-06.

What conditions does trial NCT03007472 study?

This clinical trial studies the following conditions: Hearing Loss, Sensorineural.

What interventions are being tested in trial NCT03007472?

The interventions under investigation include: CI532 (DEVICE), Nucleus 7 (DEVICE).

Who is sponsoring clinical trial NCT03007472?

This trial is sponsored by Cochlear, which has 34 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03007472 being conducted?

This trial has 10 study locations across Colorado, Iowa, Michigan, Missouri, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hearing Loss, Sensorineural

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.